



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/52, 9/00, A61K 48/00, 31/70		A1	(11) International Publication Number: WO 95/13379
			(43) International Publication Date: 18 May 1995 (18.05.95)
(21) International Application Number: PCT/US94/12976		(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 9 November 1994 (09.11.94)			
(30) Priority Data: 08/152,450 12 November 1993 (12.11.93) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: RIBOZYME PHARMACEUTICALS, INC. [US/US]; 2950 Wilderness Place, Boulder, CO 80301 (US).			
(72) Inventors: SULLENGER, Bruce, A.; Apartment 107, 2840 West 116th Place, Westminster, CO 80234 (US). CECH, Thomas, R.; 1545 Rockmont Circle, Boulder, CO 80303 (US).			
(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).			
(54) Title: ALTERATION OF SEQUENCE OF A TARGET MOLECULE			
(57) Abstract			
<p>Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTIONAlteration of Sequence of a Target Molecule

This invention relates to therapy of diseases using ribozymes.

The following is a brief history of the discovery and activity of enzymatic RNA molecules or ribozymes. This 5 history is not meant to be complete but is provided only for understanding of the invention that follows. This summary is not an admission that all of the work described below is prior art to the claimed invention.

Prior to the 1970s it was thought that all genes were 10 direct linear representations of the proteins that they encoded. This simplistic view implied that all genes were like ticker tape messages, with each triplet of DNA "letters" representing one protein "word" in the translation. Protein synthesis occurred by first transcribing a 15 gene from DNA into RNA (letter for letter) and then translating the RNA into protein (three letters at a time). In the mid 1970s it was discovered that some genes were not exact, linear representations of the proteins that they encode. These genes were found to contain interruptions 20 in the coding sequence which were removed from, or "spliced out" of, the RNA before it became translated into protein. These interruptions in the coding sequence were given the name of intervening sequences (or introns) and the process of removing them from the RNA was termed 25 splicing. A general reference for spliceosomes and how they are related to self-splicing introns is Guthrie, C., 253 Science 157, 1991. After the discovery of introns, two questions immediately arose: (i) why are introns present in genes in the first place, and (ii) how do they 30 get removed from the RNA prior to protein synthesis? The first question is still being debated, with no clear answer yet available. The second question, how introns get removed from the RNA, is much better understood after

a decade and a half of intense research on this question. At least three different mechanisms have been discovered for removing introns from RNA. Two of these splicing mechanisms involve the binding of multiple protein factors 5 which then act to correctly cut and join the RNA. A third mechanism involves cutting and joining of the RNA by the intron itself, in what was the first discovery of catalytic RNA molecules.

Cech and colleagues were trying to understand how RNA 10 splicing was accomplished in a single-celled pond organism called Tetrahymena thermophila. They had chosen Tetrahymena thermophila as a matter of convenience, since each individual cell contains over 10,000 copies of one intron-containing gene (the gene for ribosomal RNA). They 15 reasoned that such a large number of intron-containing RNA molecules would require a large amount of (protein) splicing factors to get the introns removed quickly. Their goal was to purify these hypothesized splicing factors and to demonstrate that the purified factors could splice the 20 intron-containing RNA in vitro. Cech rapidly succeeded in getting RNA splicing to work in vitro, but something funny was going on. As expected, splicing occurred when the intron-containing RNA was mixed with protein-containing extracts from Tetrahymena, but splicing also occurred when 25 the protein extracts were left out. Cech proved that the intervening sequence RNA was acting as its own splicing factor to snip itself out of the surrounding RNA. They published this startling discovery in 1982. Continuing studies in the early 1980's served to elucidate the 30 complicated structure of the Tetrahymena intron and to decipher the mechanism by which self-splicing occurs. Many research groups helped to demonstrate that the specific folding of the Tetrahymena intron is critical for bringing together the parts of the RNA that will be cut 35 and spliced. Even after splicing is complete, the released intron maintains its catalytic structure. As a consequence, the released intron is capable of carrying

out additional cleavage and splicing reactions on itself (to form intron circles). By 1986, Cech was able to show that a shortened form of the Tetrahymena intron could carry out a variety of cutting and joining reactions on 5 other pieces of RNA. The demonstration proved that the Tetrahymena intron can act as a true enzyme: (i) each intron molecule was able to cut many substrate molecules while the intron molecule remained unchanged, and (ii) reactions were specific for RNA molecules that contained 10 a unique sequence (CUCU) which allowed the intron to recognize and bind the RNA. Zaugg and Cech coined the term "ribozyme" to describe any ribonucleic acid molecule that has enzyme-like properties. Also in 1986, Cech showed that the RNA substrate sequence recognized by the 15 Tetrahymena ribozyme could be changed by altering a sequence within the ribozyme itself. This property has led to the development of a number of site-specific ribozymes that have been individually designed to cleave at other RNA sequences. The Tetrahymena intron is the 20 most well-studied of what is now recognized as a large class of introns, Group I introns. The overall folded structure, including several sequence elements, is conserved among the Group I introns, as is the general mechanism of splicing. Like the Tetrahymena intron, some 25 members of this class are catalytic, i.e. the intron itself is capable of the self-splicing reaction. Other Group I introns require additional (protein) factors, presumably to help the intron fold into and/or maintain its active structure. While the Tetrahymena intron is 30 relatively large, (413 nucleotides) a shortened form of at least one other catalytic intron (SunY intron of phage T4, 180 nucleotides) may prove advantageous not only because of its smaller size but because it undergoes self-splicing at an even faster rate than the Tetrahymena intron.

35 Ribonuclease P (RNaseP) is an enzyme comprised of both RNA and protein components which are responsible for converting precursor tRNA molecules into their final form by

trimming extra RNA off one of their ends. RNaseP activity has been found in all organisms tested, but the bacterial enzymes have been the most studied. The function of RNaseP has been studied since the mid-1970s by many labs.

5 In the late 1970s, Sidney Altman and his colleagues showed that the RNA component of RNaseP is essential for its processing activity; however, they also showed that the protein component also was required for processing under their experimental conditions. After Cech's discovery of

10 self-splicing by the Tetrahymena intron, the requirement for both protein and RNA components in RNaseP was reexamined. In 1983, Altman and Pace showed that the RNA was the enzymatic component of the RNaseP complex. This demonstrated that an RNA molecule was capable of acting as

15 a true enzyme, processing numerous tRNA molecules without itself undergoing any change. The folded structure of RNaseP RNA has been determined, and while the sequence is not strictly conserved between RNAs from different organisms, this higher order structure is. It is thought that

20 the protein component of the RNaseP complex may serve to stabilize the folded RNA in vivo. At least one RNA position important both to substrate recognition and to determination of the cleavage site has been identified, however little else is known about the active site.

25 Because tRNA sequence recognition is minimal, it is clear that some aspect(s) of the tRNA structure must also be involved in substrate recognition and cleavage activity. The size of RNaseP RNA (>350 nucleotides), and the complexity of the substrate recognition, may limit the

30 potential for the use of an RNaseP-like RNA in therapeutics. However, the size of RNaseP is being trimmed down (a molecule of only 290 nucleotides functions reasonably well). In addition, substrate recognition has been simplified by the recent discovery that RNaseP RNA

35 can cleave small RNAs lacking the natural tRNA secondary structure if an additional RNA (containing a "guide"

sequence and a sequence element naturally present at the end of all tRNAs) is present as well.

Symons and colleagues identified two examples of a self-cleaving RNA that differed from other forms of 5 catalytic RNA already reported. Symons was studying the propagation of the avocado sunblotch viroid (ASV), an RNA virus that infects avocado plants. Symons demonstrated that as little as 55 nucleotides of the ASV RNA was capable of folding in such a way as to cut itself into two 10 pieces. It is thought that in vivo self-cleavage of these RNAs is responsible for cutting the RNA into single genome-length pieces during viral propagation. Symons discovered that variations on the minimal catalytic 15 sequence from ASV could be found in a number of other plant pathogenic RNAs as well. Comparison of these sequences revealed a common structural design consisting of three stems and loops connected by central loop containing many conserved (invariant from one RNA to the next) nucleotides. The predicted secondary structure for 20 this catalytic RNA reminded the researchers of the head of a hammer; thus it was named as such. Uhlenbeck was successful in separating the catalytic region of the ribozyme from that of the substrate. Thus, it became possible to assemble a hammerhead ribozyme from 2 (or 3) 25 small synthetic RNAs. A 19-nucleotide catalytic region and a 24-nucleotide substrate were sufficient to support specific cleavage. The catalytic domain of numerous hammerhead ribozymes have now been studied by both the Uhlenbeck and Symons groups with regard to defining the 30 nucleotides required for specific assembly and catalytic activity and determining the rates of cleavage under various conditions.

Haseloff and Gerlach showed it was possible to divide the domains of the hammerhead ribozyme in a different 35 manner. By doing so, they placed most of the required sequences in the strand that didn't get cut (the ribozyme) and only a required UH where H = C, A, or U in the strand

that did get cut (the substrate). This resulted in a catalytic ribozyme that could be designed to cleave any UH RNA sequence embedded within a longer "substrate recognition" sequence. The specific cleavage of a long mRNA, in 5 a predictable manner using several such hammerhead ribozymes, was reported in 1988.

One plant pathogen RNA (from the negative strand of the tobacco ringspot virus) undergoes self-cleavage but cannot be folded into the consensus hammerhead structure 10 described above. Bruening and colleagues have independently identified a 50-nucleotide catalytic domain for this RNA. In 1990, Hampel and Tritz succeeded in dividing the catalytic domain into two parts that could act as substrate and ribozyme in a multiple-turnover, cutting 15 reaction. As with the hammerhead ribozyme, the hairpin catalytic portion contains most of the sequences required for catalytic activity while only a short sequence (GUC in this case) is required in the target. Hampel and Tritz described the folded structure of this RNA as consisting 20 of a single hairpin and coined the term "hairpin" ribozyme (Bruening and colleagues use the term "paper clip" for this ribozyme motif). Continuing experiments suggest an increasing number of similarities between the hairpin and hammerhead ribozymes in respect to both binding of target 25 RNA and mechanism of cleavage. At the same time, the minimal size of the hairpin ribozyme is still 50-60% larger than the minimal hammerhead ribozyme.

Hepatitis Delta Virus (HDV) is a virus whose genome consists of single-stranded RNA. A small region (~80 30 nucleotides) in both the genomic RNA, and in the complementary anti-genomic RNA, is sufficient to support self-cleavage. As the most recently discovered ribozyme, HDV's ability to self-cleave has only been studied for a few years, but is interesting because of its connection to 35 a human disease. In 1991, Been and Perrotta proposed a secondary structure for the HDV RNAs that is conserved between the genomic and anti-genomic RNAs and is necessary

for catalytic activity. Separation of the HDV RNA into "ribozyme" and "substrate" portions has recently been achieved by Been, but the rules for targeting different substrate RNAs have not yet been determined fully. Been 5 has also succeeded in reducing the size of the HDV ribozyme to ~60 nucleotides.

The table below lists some of the characteristics of the ribozymes discussed above:

TABLE 1

10 Characteristics of ribozymes

Group I Introns

Size: ~300 to >1000 nucleotides.

Requires a U in the target sequence immediately 5' of the cleavage site.

15 Binds 4-6 nucleotides at 5' side of cleavage site.

Over 75 known members of this class. Found in Tetrahymena thermophila rRNA, fungal mitochondria, chloroplasts, phage T4, blue-green algae, and others.

RNAseP RNA (M1 RNA)

20 Size: ~290 to 400 nucleotides.

RNA portion of a ribonucleoprotein enzyme. Cleaves tRNA precursors to form mature tRNA.

Roughly 10 known members of this group all are bacterial in origin.

25 Hammerhead Ribozyme

Size: ~30 to 40 nucleotides.

Requires the target sequence UH immediately 5' of the cleavage site.

30 Binds a variable number nucleotides on both sides of the cleavage site.

14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent.

Hairpin Ribozyme

Size: ~50 nucleotides.

Requires the target sequence GUC immediately 3' of the cleavage site.

5 Binds 4 nucleotides at 5' side of the cleavage site and a variable number to the 3' side of the cleavage site.

Only 1 known member of this class. Found in one plant pathogen (satellite RNA of the tobacco ringspot virus) which uses RNA as the infectious agent.

10 Hepatitis Delta Virus (HDV) Ribozyme

Size: ~60 nucleotides (at present).

Cleavage of target RNAs recently demonstrated.

Sequence requirements not fully determined.

15 Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required.

Only 1 known member of this class. Found in human HDV.

As the term is used in this application, ribozymes are RNA molecules having an enzymatic activity which is able 20 to cleave and splice other separate RNA molecules in a nucleotide base sequence specific manner. Such enzymatic RNA molecules can be targeted to virtually any RNA transcript, and efficient cleavage and splicing achieved in vitro. Kim et al., 84 Proc. Nat. Acad. of Sci. USA 25 8788, 1987, Hazeloff et al., 234 Nature 585, 1988, Cech, 260 JAMA 3030, 1988, and Jefferies et al., 17 Nucleic Acid Research 1371, 1989.

Ribozymes act by first binding to a target RNA. Such binding occurs through the target RNA binding portion of 30 a ribozyme which is held in close proximity to an enzymatic portion of the RNA which acts to cleave the target RNA. Thus, the ribozyme first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts to cut and splice the 35 target RNA. Strategic cleavage and splicing of such a

target RNA will destroy its ability to direct synthesis of an encoded protein. After a ribozyme has bound, cleaved and spliced its RNA target it is released from that RNA.

By the phrase "catalytic" or "enzymatic RNA molecule" 5 is meant an RNA molecule which has complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity which is active to specifically cleave and splice RNA in that target. That 10 is, the enzymatic RNA molecule is able to intermolecularly cleave and splice RNA and thereby alter a target RNA molecule. This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA to allow the cleavage to occur. 100% complementarity is preferred, but complementarity as low 15 as 50-75% may also be useful in this invention.

In preferred embodiments of this invention, the enzymatic RNA molecule is formed in a hammerhead motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP RNA (in 20 association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi et al., 8 AIDS RESEARCH AND HUMAN RETROVIRUSES 183, 1992, of hairpin motifs by Hampel et al., RNA CATALYST FOR CLEAVING SPECIFIC RNA SEQUENCES, filed September 20, 1989, which is 25 a continuation-in-part of U.S. Serial No. 07/247,100 filed September 20, 1988, Hampel and Tritz, 28 Biochemistry 4929, 1989 and Hampel et al., 18 Nucleic Acids Research 299, 1990, and an example of the hepatitis delta virus motif is described by Perrotta and Been, 31 Biochemistry 16, 1992, of the RNaseP motif by Guerrier-Takada et al., 35 Cell 849, 1983, and of the group I intron by Cech et al., U.S. Patent 4,987,071. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic 30 RNA molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have

nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.

The invention provides a method for designing a class 5 of enzymatic cleaving and splicing agents which exhibit a high degree of specificity for the RNA of a desired target. The ribozyme molecule is preferably targeted to a highly conserved sequence region of a target such that specific treatment of a disease or condition can be 10 provided with a single ribozyme. Such enzymatic RNA molecules can be delivered exogenously to specific cells as required.

Synthesis of ribozymes greater than 100 nucleotides in length is very difficult using automated methods, and the 15 therapeutic cost of such molecules is prohibitive. However, delivery of such ribozymes by expression vectors is primarily feasible using ex vivo treatments.

Inoue et al., 43 Cell 431, 1985, state that short oligonucleotides of 2-6 nucleotides can undergo inter- 20 molecular exon ligation or splicing in trans. It indicates that "long 5' exons should be reactive provided that three conditions are met: the exon must have a 3' hydroxyl group, it must terminate in a sequence similar to that of the 3' end of the 5' exon, and the 3' terminal 25 sequence must be available as opposed to being tied up in some secondary structure. Thus, it appears that exon switching is possible in this system, though limited by the availability of alternative 5' exons that meet the above criteria. These could include transcripts that are 30 not 5' exons from other precursors, since RNA polymerases always leave 3' hydroxyl ends".

Summary of the Invention

This invention features a method in which natural transcripts are altered by use of a splicing reaction in 35 vivo or in vitro. It involves the manipulation of genetic

information to ensure that a useful transcript is provided within a cellular system or extract.

In a first aspect, the invention features a method for splicing a target nucleic acid molecule with a separate 5 nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with 10 a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric 15 nucleic acid molecule. In this method, the catalytic nucleic acid molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.

The target nucleic acid molecule can be any desired 20 molecule with which a splicing reaction can occur. Generally, this will be an RNA molecule, preferably a messenger RNA molecule, but it may also include molecules that have one or more non-ribonucleotides substituents, such as deoxyribonucleotides or other analogs as described 25 by Usman et al., PCT/US93/00833 and Eckstein et al. EP90/01731, both hereby incorporated by reference.

Generally, the target nucleic acid molecule is present within a cell and is chosen or targeted because it encodes a defective protein or is deleterious to that cell. 30 Splicing of the separate nucleic acid molecule with such a target nucleic acid molecule is designed to alter the protein product of that nucleic acid molecule. Such alteration causes production of a useful protein which will allow that cell to either survive or die, as desired. 35 Thus, for example, in a gene therapy setting, the target nucleic acid molecule may encode a non-functional protein necessary for normal life. This molecule can be spliced

with a separate nucleic acid molecule to allow appropriate expression of a functional protein. Alternatively, the splicing may cause production of a more stable protein, or of a protein which acts as an agonist or antagonist of 5 a function, e.g., a viral or bacterial replication function.

The separate nucleic acid molecule is generally chosen such that it encodes a 3' exon which it is desirable to express within a cell. This exon will generally not 10 include control sequences such as promoter regions, but may include poly(A) tails and other stabilizing or enhancing functions well known in the art. As with the target nucleic acid molecule, the separate nucleic acid molecule generally is a ribonucleic acid molecule but may 15 be substituted as described above.

By "enzymatic" or "catalytic nucleic acid molecule" is meant a molecule having a motif generally as described above in the Background of the Invention, which and is preferably selected from the motif of a group I or group 20 II intron having a cleavage and splicing activity. Alternatively, the splicing or cleavage activity may be provided by a different nucleic acid molecule, or may supplement the catalytic nucleic acid molecule. Those of ordinary skill in the art will recognize that other motifs 25 than those of the group I and group II introns may also be manipulated to provide useful splicing activity.

The conditions chosen for the contacting step may be those naturally occurring within a cell, or may be manipulated in vitro to ensure that the splicing reaction will 30 occur. These conditions are well known to those in the art, for example, as described by Inoue et al., supra.

By at least a portion of the respective nucleic acid molecules is meant that the 5' end of the target nucleic acid molecule will be spliced with the 3' end of the 35 separate nucleic acid molecule. Such a portion may be only a few nucleotides (10-500 nucleotides) or may be significantly greater and may represent almost all of a

molecule encoding a gene product (*i.e.*, at least 1 to 5 kbases).

The chimeric nucleic acid molecule is one which may occur naturally in nature but is not present prior to the 5 splicing reaction. Alternatively, it may be a completely novel structure which does not occur in nature, but which is useful in gene therapeutic treatment of an organism.

The catalytic nucleic acid molecule is not naturally associated with the separate nucleic acid molecule since 10 it is not generally desired to splice the 3' end of a naturally occurring catalytic nucleic acid molecule with a target nucleic acid molecule. Rather, the separate nucleic acid molecule is chosen or selected to have a beneficial function once spliced with the target nucleic 15 molecule.

In a related aspect, the invention features a method for splicing a target nucleic acid molecule with a separate nucleic acid molecule by contacting those molecules in the presence of one or more splicing factors or 20 spliceosomes under splicing conditions. Such molecules are not naturally spliced together in nature, although the final splice product may be a natural product.

The various splicing factors and spliceosomes are well known in the art, and this activity is generally described 25 by Bruzik and Maniatis in 360 Nature 692, 1992, hereby incorporated by reference herein. The invention concerns splicing of target nucleic acid molecules and separate nucleic acid molecules which are not normally spliced together within a cell as described by Bruzik and 30 Maniatis, supra. Rather, as described above, a separate nucleic acid molecule is selected such that a useful function can be achieved in a gene therapeutic fashion.

In preferred embodiments, the catalytic nucleic acid is able to cleave and splice, *e.g.*, it has a group I or 35 group II intron motif; the method is performed in vitro or in vivo with an RNA target; and the method can be used to treat genetic disease in a gene therapy type manner, for

example, by correcting an abnormal transcript, or by providing antiviral activity such as a dominant negative allele to a viral RNA.

In other aspects, the invention features catalytic 5 nucleic acid molecules having a selected separate nucleic acid molecule as a 3' exon encoding at least a portion of a useful gene which can be used in gene therapy. Such a molecule can be spliced with and thereby correct or modify the expression of other target RNA molecules. The 10 invention also features vectors encoding such catalytic nucleic acid molecules.

The observation that ribozymes can specifically cleave targeted RNAs in vitro has led to much speculation about their potential usefulness as gene inhibitors. By 15 cleaving targeted mRNAs in vivo, ribozymes can be used to stop the flow of genetic information. Here we describe a different application of ribozymes. For example, a group I intron ribozyme can be used to manipulate the flow of genetic information by targeted trans-splicing. Defective 20 cellular transcripts may be repaired, or pathogen-derived transcripts may be altered to encode antagonists to the pathogen using such technology.

In nature the group I intron ribozyme from Tetrahymena thermophila self-splices itself from precursor ribosomal 25 RNAs (T.R. Cech, A.J. Zaug, P.J. Grabowski, Cell 27 487 (1981); K. Kruger et al., Cell 31, 147 (1982)). This process is accomplished in two successive steps. First the phosphodiester bond at the 5' exon-intron border is cleaved. Then the 3' hydroxyl group on the 5' exon is 30 covalently attached to the 3' exon, and the intron is removed (Fig. 1A). It has been previously demonstrated in vitro that the 5' exon in this reaction can be mimicked by RNA molecules supplied in trans; the minimum active unit is the dinucleotide substrate rCU (Fig. 1B) (T. Inoue, 35 F.X. Sullivan, T.R. Cech, Cell 43, 431 (1985)). We propose use of trans-splicing reactions to ligate foreign sequences onto targeted transcripts after cleavage (Fig.

1C). In this manner, ribozymes can be employed to manipulate the flow of genetic information inside cells by changing what a targeted RNA encodes.

Other features and advantages of the invention will be 5 apparent from the following description of the preferred embodiments thereof, and from the claims.

Description of the Preferred Embodiments

The drawings will briefly be described.

Drawings

10 FIGS. 1A, 1B, and 1C are diagrammatic representations showing reactions of the group I intron from Tetrahymena for targeted trans-splicing.

FIGS. 2A and 2B are a comparison of cis- and trans-splicing reactions for LacZ transcripts.

15 FIG. 3 is a copy of an autoradiogram showing targeted trans-splicing to correct truncated transcripts from the alpha complement of LacZ 39 nucleotides long. L-21 (or L-21 del) ribozyme-3' exon chimeric RNAs (see Fig. 2B) (³²P-body-labeled) (200nM) were preheated in reaction buffer 20 [50mM Hepes (pH 7.0), 150mM NaCl, and 5mM MgCl₂] at 50°C for 5 minutes and then equilibrated at 37°C for 2 minutes. The 13 (5'-A₅: GGCCCUCUA₅) or 39 (5'L-A₂: see Fig. 2B) nucleotide substrate RNAs (1μM) and GTP (100μM) were preheated to 37°C and added to the ribozymes to start the 25 reactions which proceeded at 37°C. Portions containing one fifteenth of the reactions were removed at 0, 2, 10, 60, and 180 minutes and added to an equal volume of 10mM EDTA to stop the reactions. Reaction products were analyzed upon a 4% polyacrylamide gel with 8M urea. The 30 inactive L-21 del ribozyme was generated by deleting 93 nucleotide of the ribozyme (nucleotides 237-330 comprising L6b to P9).

FIG. 4 is a graphical representation of the targeted trans-splicing rate for correcting the 39 nucleotide truncated LacZ transcript. The products from the trans-

splicing reaction time course containing the action L-21 ribozyme and the 39 nucleotide substrate shown in figure 2 were quantified with an AMBIS Image Acquisition and Analysis System (AMBIS, Inc., San Diego, CA). The 5 percentage of the ribozyme-3' exon RNA remaining is plotted versus time.

FIG. 5 is a copy of an autoradiogram showing hydrolysis of the 3' LacZ exon attached to the L-21 ribozyme. L-21 (or L-21 del) ribozyme-3' exon chimeric 10 RNAs (^{32}P -body-labeled) (100nM) were incubated at 37°C in reaction buffer [50mM Hepes (pH 7.0), 150mM NaCl, 5mM MgCl₂, and 100 μM GTP]. A portion of the reaction was removed after 0, 2, 10, and 60 minutes and added to an equal volume of 10mM EDTA to stop the reaction. Products 15 were analyzed upon a 4% polyacrylamide gel containing 8M urea.

FIGS. 6A and 6B are representations of trans-splicing to recreate an entire 3074 nucleotide LacZ messenger RNA from a 1106 nucleotide truncated transcript. A. Scheme 20 for correcting transcript. B. Trans-splicing reaction. L-21 (or L-21 del) ribozyme-3' exon chimeric RNAs (20nM) were preheated in reaction buffer [50mM Hepes (pH 7.0), 150mM NaCl, and 5mM MgCl₂] at 50°C for 5 minutes and then equilibrated at 37°C for 2 minutes. The 1106 nucleotide 25 substrate RNA (^{32}P -end labeled) (200nM) and GTP (100 μM) were preheated at 37°C and added to the ribozymes to start the reactions which proceeded at 37°C. One sixth of each reaction was removed at 0, 2, 10, 60, and 180 minutes and added to an equal volume of 10mM EDTA to stop the 30 reaction. Reaction products were analyzed upon a 1.2% agarose gel containing 1.1% formaldehyde. rRNAs from mouse NIH 3T3 cells were used to as 5100 and 1900 nt molecular weight markers. The remaining sixth of the reactions, which had proceeded for 120 minutes, were in 35 vitro translated.

FIG. 7 is a scheme for correcting genetic mutations using targeted trans-splicing.

FIG. 8 is a scheme for mutating HIV transcripts using targeted trans-splicing.

Targeted Trans-splicing

The general scheme for a targeted trans-splicing is 5 shown in Fig. 1 using the group I intron of Tetrahymena thermophila as an example. Those in the art will recognize that this example is not limiting in the invention and that other enzymatic RNA molecules having the appropriate splicing activity can be used in the invention. 10 Alternatively, as discussed above, these molecules can be supplemented by other molecules having a suitable splicing activity, or by spliceosomes or splicing factors. Generally, the reaction involves base pairing of the catalytic nucleic acid molecule with the targeted 15 transcript, cleavage of the targeted transcript, and then ligation of the 3' exon (separate nucleic acid molecule) with this targeted 5' exon. The catalytic nucleic acid is removed in the reaction. As will be noted, the specificity of the reaction can be changed by alteration 20 of the substrate binding site in the catalytic nucleic acid molecule by methods well known in the art.

The following is an example of various constructs used to show the operability of the claimed invention. Those in the art will recognize that this example indicates the 25 utility of the invention for both in vitro and in vivo splicing reactions. While significant utility will be attained in vivo by use of the present invention, those in the art will also recognize that in vitro utility is important and can be used to create chimeric transcripts 30 for use in laboratory situations or in a clinical setting.

Example 1: LacZ Fusion

To assess the feasibility of the targeted trans-splicing approach, we tested the ability of the Tetrahymena ribozyme to correct truncated LacZ transcripts 35 with targeted trans-splicing. It has previously been shown that in E. coli the Tetrahymena self-splicing group

I intron can efficiently splice itself from transcripts encoding the alpha-complement of β -galactosidase (β -gal) (Fig. 2A) (J.V. Price, T.R. Cech, *Science* **228**, 719 (1985); Waring et al., *Cell* **40**, 371 (1985)). Since this reaction 5 proceeded very efficiently in cis, we decided to determine if the ribozyme could perform a similar reaction in trans.

This system consists of 2 RNA molecules (Fig. 2B): a ribozyme-3' exon RNA and a 5' exon RNA. The group I ribozyme used in this study lacks the first 21 nucleotides 10 present in the full length intron from which it is derived (A.J. Zaug, T.R. Cech, *Science* **231**, 470 (1986)). The first 23 nucleotides of the 3' exon are derived from the pre-rRNA 3' exon sequence from *Tetrahymena* (M.D. Been, T.R. Cech, *Cell* **47**, 207 (1986)). This 23 nucleotide 15 sequence is fused in-frame to 200 nucleotides of the alpha-complement of the LacZ gene (Been and Cech, supra). The 39 nucleotide 5' exon contains a ribosome binding site, the first 21 coding nucleotides of an alpha-complement LacZ transcript, the ribozyme recognition 20 sequence CCCUCU, and two adenosines. These adenosines must be removed if trans-splicing is to correct these LacZ transcripts. (Fig. 2B). [Previous studies have shown that the sequence and length of the RNA following the CCCUCU is not critical for Tetrahymena ribozyme action 25 (A.J. Zaug, M.D. Been, T.C. Cech, *Nature* **324**, 429 (1986))].

In vitro, the ribozyme can quickly and accurately trans-splice this LacZ 3' exon onto the truncated 39 nucleotide LacZ 5' exon to generate an RNA product which 30 encodes the alpha-complement of β -galactosidase (Fig. 3). The reaction proceeds with speed and efficiency similar to those seen in a reaction with a short 13 nucleotide substrate. The $t_{1/2}$ for the trans-splicing reaction with the 39 nucleotide substrate was determined to be 13 35 minutes under conditions of substrate excess (Fig. 4).

In these experiments, trans-splicing (production of 5'-3' or 5'L-3') occurred faster than hydrolysis (produc-

tion of free 3' exon; see Fig. 2). The rate of hydrolysis of the 3' exon from the ribozyme was determined to be $t_{1/2}$ - 60 minutes in a separate experiment (Fig. 5). An inactive version of the L-21 ribozyme (L-21 del) was not able to 5 perform either the trans-splicing or the hydrolysis reaction (Fig. 3 and 5). Sequencing of the trans-splicing product confirmed that the ultimate and penultimate 3' adenosine nucleotide were correctly removed from the 5' exon-substrate RNA, and this cleaved 5' exon was 10 accurately spliced onto the 3' exon (data not shown). The splice junction gave the proper reading frame for β -gal expression.

Example 2: mRNA Splicing

To determine if targeted trans-splicing could be 15 employed to correct mRNA-size RNA fragments, a transcript which contained the first 1106 nucleotides of the LacZ coding sequence as well as signals for in vitro translation was created and targeted for alteration by trans-splicing. The L-21 ribozyme was directed to cleave 20 the truncated LacZ transcript 19 nucleotides from its 3' end and trans-splice a 3' exon brought in by the ribozyme onto the cleaved LacZ target RNA (Fig. 6A). The 3' exon sequence attached to the ribozyme encoded the last 1987 nucleotides of the LacZ coding sequence and no sequences 25 from the Tetrahymena pre rRNA. Accurate trans-splicing of the 3' exon sequences onto the truncated transcript resulted in a 3074 nucleotide product which encoded the entire LacZ coding sequence (Fig. 6B).

Once again the inactive version of the ribozyme (L-21 30 del) was unable to perform this reaction, confirming its expected dependence of the catalytic activity of the RNA itself. The trans-splicing products from the 120 minute time points of the reactions shown in figure 6 were in vitro translated in wheat germ extract, and the in vitro 35 translated proteins were assayed for β -gal activity using

a standard ONPG assay (C. Smith et al., Leukemia 7, 310 (1993)).

Proteins from trans-splicing reactions containing active ribozymes were shown to contain 1500 units [1000 x 5 OD420/(ml-min)] of β -gal activity, while no activity was found in proteins translated from reactions containing the inactive ribozyme. Therefore, trans-splicing can be employed to correct the coding sequence of large defective transcripts.

10 In the reaction shown in figure 6, the labeled substrate RNA is in a 10 fold excess to the ribozyme-3' exon RNA. Therefore, only 10% of the labeled substrate RNAs could at best be converted to trans-spliced products. In this reaction however, we roughly estimate (by 15 comparing different X-ray film exposures of the gel) that at most 1% of the truncated RNAs are corrected. This lack of efficiency is probably a result of the targeted RNAs adopting conformations which inhibit the ribozyme from correctly interacting with them. To improve the 20 efficiency of this trans-splicing reaction, alternative sites for cleavage and splicing which are more accessible to the ribosome can be targeted by standard manipulation of this experiment. In vivo, cellular proteins may improve the efficiency of formation of the correct RNA 25 interaction (Z. Tsuchihashi, M. Khosla, D. Herschlag, Science 262, 99 (1993)).

Uses

Gene mapping and human genome sequencing provides the 30 genetic basis for an increasing number of inherited diseases. With each discovery or identification of a new disease-related gene there is an opportunity to develop gene therapy based treatments. Conventional gene therapy approaches attempt to correct a genetic deficiency by transferring a wild-type cDNA copy of a gene under the 35 control of a heterologous promoter to cells harboring a defective copy of the gene. One obstacle for implementing

such treatments is an inability to faithfully recapitulate the normal expression pattern of endogenous genes after gene transfer (R.A. Morgan, W.F. Anderson, *Ann. Rev. Biochem.* **62**, 191 (1993); E.A. Dzierzak, T. Papayannopoulou, 5 R.C. Mulligan, *Nature* **331**, 35 (1989)). This may limit the number of genetic diseases treatable by gene therapy. Targeted trans-splicing offers a solution to this problem.

Ribozymes can be used to correct the defective transcripts issuing from mutant genes. This approach will 10 be valuable for the treatment of the many genetic diseases caused by a common set of specific mutations which do not affect the expression of the mutant gene. For example, the genetic basis of many globin diseases is well understood. However, gene therapy based treatments for 15 such diseases have been slow in coming, perhaps, because the expression patterns of the globin genes cannot be recapitulated after gene transfer. Targeted trans-splicing can potentially repair or correct globin transcripts that are either truncated or contain point 20 mutations. In the process, the cellular expression pattern of these genes is maintained (Fig. 7). Therefore, targeted trans-splicing represents an important, novel strategy for the treatment of many genetic diseases.

Trans-splicing ribozymes based on any of the self-splicing group I introns can be designed to cleave a targeted transcript upstream of a specific mutation or upstream of a premature 3' end at essentially any uridine residue (F.L. Murphy, T.R. Cech, *Proc. Natl. Acad. Sci. USA* **86**, 9218 (1989)). One simply changes the sequence of 25 the internal guide sequence within the ribozyme (5'-GNNNNN) to match the sequence preceding the site of target RNA cleavage (5'-N'N'N'N'N'U), where N-N' represent any allowable base pair. The 3' exons attached to the ends of 30 these ribozymes are comprised of a sequence designed to correct the mutant transcripts being targeted. The ribozyme will both cleave the mutant transcript and replace 35 the mutant 3' region by a functional sequence. There is

very little sequence requirement for a 3' exon in these reactions, so virtually any sequence can serve (J.V. Price, T.R. Cech, *Genes and Development* 2, 1439 (1988)). Thus, trans-splicing ribozymes can be made to correct essentially any mutant transcript because sequence requirements for 5' cleavage sites and 3' exons are minimal.

Trans-splicing ribozymes are also be effective antiviral agents. Several groups have employed trans-cleaving ribozymes to inhibit viral replication. Use of such ribozymes results in the destruction of the targeted viral RNA inside cells (N. Sarver et al., *Science* 247, 1222 (1990)). Thus, the effectiveness of these trans-cleavage ribozymes rests upon their ability to destroy the vast majority of the targeted viral RNAs. We propose employing trans-splicing ribozymes not to destroy viral RNAs, but to change the sequence of the viral RNAs to give them antiviral activity. For example, the HIV transcripts that encode the gag protein can be changed to encode a dominant negative version of this protein via targeted trans-splicing (Fig. 8) (M.H. Malim, E. Bohnlein, J. Hauber, B.R. Culien, *Cell* 58, 205 (1989); D. Trono, M.B. Feinberg, D. Baltimore, *Cell* 59, 113 (1989)) or to contain a large number of TAR or RRE decoy RNAs (B.A. Sullenger, H.F. Gallardo, G.E. Ungers, E. Gilboa, *Cell* 63, 601 (1990)).

In contrast to trans-cleaving ribozymes, such antiviral trans-splicing ribozymes would have to affect only a small percentage of the targeted HIV transcripts to be effective at inhibiting viral replication. In general, the ability to change the information encoded by targeted transcripts by trans-splicing represents a broad new approach to gene inhibition because now transcripts can be altered to encode proteins or RNAs which can inhibit the function of the targeted gene. In other words, with targeted trans-splicing, deleterious transcripts can be turned against themselves.

As noted above, trans-splicing may also be accomplished without the use of ribozymes. It has been demonstrated that spliced leader sequences from lower eucaryotes can be trans-spliced onto mammalian 3' splice 5 sites in tissue culture cells (J.P. Bruzik, T. Maniatis, Nature 360, 692 (1992)). Trans-splicing in this case is mediated by the spliceosome or splicing factors. Thus, it is possible to employ spliceosomes to alter the sequence of targeted transcripts for some desired end via targeted 10 trans-splicing.

Thus, this invention provides a means for performing molecular reconstructive surgery. A defective part of a useful RNA molecule can be cut away from the rest of the molecule and subsequently replaced by a functional part. 15 Alternatively, a functional portion of a disease-causing or deleterious RNA can be replaced by an inhibitory portion.

Administration

The above trans-splicing factors or agents can be 20 administered by standard techniques, some of which are discussed below. They may be administered as RNA or expressed from expression vectors. Selected agents, e.g., oligonucleotides or ribozymes can be administered prophylactically, or to patients suffering from a target 25 disease, e.g., by exogenous delivery of the agent to an infected tissue by means of an appropriate delivery vehicle, e.g., a liposome, a controlled release vehicle, by use of iontophoresis, electroporation or ion paired molecules, or covalently attached adducts, and other 30 pharmacologically approved methods of delivery. Routes of administration include intramuscular, aerosol, oral (tablet or pill form), topical, systemic, ocular, intra-peritoneal and/or intrathecal. Expression vectors for immunization with ribozymes and/or delivery of oligo- 35 nucleotides are also suitable.

The specific delivery route of any selected agent will depend on the use of the agent. Generally, a specific delivery program for each agent will focus on naked agent uptake with regard to intracellular localization, followed 5 by demonstration of efficacy. Alternatively, delivery to these same cells in an organ or tissue of an animal can be pursued. Uptake studies will include uptake assays to evaluate, e.g., cellular oligonucleotide uptake, regardless of the delivery vehicle or strategy. Such assays 10 will also determine the intracellular localization of the agent following uptake, ultimately establishing the requirements for maintenance of steady-state concentrations within the cellular compartment containing the target sequence (nucleus and/or cytoplasm). Efficacy and 15 cytotoxicity can then be tested. Toxicity will not only include cell viability but also cell function.

Some methods of delivery that may be used include:

- a. encapsulation in liposomes,
- b. transduction by retroviral vectors,
- 20 c. conjugation with cholesterol,
- d. localization to nuclear compartment utilizing antigen binding site found on most snRNAs,
- e. neutralization of charge of ribozyme by using nucleotide derivatives, and
- 25 f. use of blood stem cells to distribute ribozymes throughout the body.

At least three types of delivery strategies are useful in the present invention, including: ribozyme modifications, particle carrier drug delivery vehicles, 30 and retroviral expression vectors. Unmodified ribozymes and antisense oligonucleotides, like most small molecules, are taken up by cells, albeit slowly. To enhance cellular uptake, the ribozyme may be modified essentially at random, in ways which reduce its charge but maintain 35 specific functional groups required for RNA cleavage and splicing activity. This results in a molecule which is

able to diffuse across the cell membrane, thus removing the permeability barrier.

Modification of ribozymes to reduce charge is just one approach to enhance the cellular uptake of these larger molecules. The random approach, however, is not advisable since ribozymes are structurally and functionally more complex than small drug molecules. The structural requirements necessary to maintain ribozyme catalytic activity are well understood by those in the art. (See, 10 Cech, Curr. Op. Structural Biol., 1992) These requirements are taken into consideration when designing modifications to enhance cellular delivery. The modifications are also designed to reduce susceptibility to nuclease degradation. Both of these characteristics 15 should greatly improve the efficacy of the ribozyme. Cellular uptake can be increased by several orders of magnitude without having to alter the phosphodiester linkages necessary for ribozyme cleavage activity.

Chemical modifications of the phosphate backbone will 20 reduce the negative charge thereby facilitating diffusion across the membrane. This principle has been successfully demonstrated for antisense DNA technology. The similarities in chemical composition between DNA and RNA make this a feasible approach. In the body, maintenance 25 of an external concentration will be necessary to drive the diffusion of the modified ribozyme into the cells of the tissue. Administration routes which allow the diseased tissue to be exposed to a transient high concentration of the drug, which is slowly dissipated by 30 systemic adsorption are preferred. Intravenous administration with a drug carrier designed to increase the circulation half-life of the ribozyme can be used. The size and composition of the drug carrier restricts rapid clearance from the blood stream. The carrier, made to 35 accumulate at the site of infection, can protect the ribozyme from degradative processes.

Drug delivery vehicles are effective for both systemic and topical administration. They can be designed to serve as a slow release reservoir, or to deliver their contents directly to the target cell. An advantage of using direct 5 delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs which would otherwise be rapidly cleared from the blood stream. Some examples of such specialized drug delivery vehicles which 10 fall into this category are liposomes, hydrogels, cyclo-dextrins, biodegradable nanocapsules, and bioadhesive microspheres.

From this category of delivery systems, liposomes are preferred. Liposomes increase intracellular stability, 15 increase uptake efficiency and improve biological activity. Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids which make up the cell membrane. They have an internal aqueous space for entrapping water soluble 20 compounds and range in size from 0.05 to several microns in diameter. Several studies have shown that liposomes can deliver RNA to cells and that the RNA remains biologically active.

For example, a liposome delivery vehicle originally 25 designed as a research tool, Lipofectin, has been shown to deliver intact mRNA molecules to cells yielding production of the corresponding protein.

Liposomes offer several advantages: They are non-toxic and biodegradable in composition; they display long 30 circulation half-lives; and recognition molecules can be readily attached to their surface for targeting to tissues. Finally, cost effective manufacture of liposome-based pharmaceuticals, either in a liquid suspension or lyophilized product, has demonstrated the viability of 35 this technology as an acceptable drug delivery system.

Other controlled release drug delivery systems, such as nonoparticles and hydrogels may be potential delivery

vehicles for a ribozyme. These carriers have been developed for chemotherapeutic agents and protein-based pharmaceuticals, and consequently, can be adapted for ribozyme delivery.

5 Topical administration of trans-splicing ribozymes is advantageous since it allows localized concentration at the site of administration with minimal systemic adsorption. This simplifies the delivery strategy of the ribozyme to the disease site and reduces the extent of
10 toxicological characterization. Furthermore, the amount of material to be applied is far less than that required for other administration routes. Effective delivery requires the ribozyme to diffuse into the infected cells. Chemical modification of the ribozyme to neutralize
15 negative charge may be all that is required for penetration. However, in the event that charge neutralization is insufficient, the modified ribozyme can be co-formulated with permeability enhancers, such as Azone or oleic acid, in a liposome. The liposomes can
20 either represent a slow release presentation vehicle in which the modified ribozyme and permeability enhancer transfer from the liposome into the infected cell, or the liposome phospholipids can participate directly with the modified ribozyme and permeability enhancer in
25 facilitating cellular delivery. In some cases, both the ribozyme and permeability enhancer can be formulated into a suppository formulation for slow release.

Such ribozymes may also be systemically administered. Systemic absorption refers to the accumulation of drugs in
30 the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, subcutaneous, intra-peritoneal, intranasal, intrathecal and ophthalmic. Each of these administration routes expose the ribozyme to an
35 accessible diseased tissue. Subcutaneous administration drains into a localized lymph node which proceeds through the lymphatic network into the circulation. The rate of

entry into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier localizes the ribozyme at the lymph node. The ribozyme can be modified to diffuse into the 5 cell, or the liposome can directly participate in the delivery of either the unmodified or modified ribozyme to the cell.

A liposome formulation which can associate ribozymes with the surface of lymphocytes and macrophages is also 10 useful. This will provide enhanced delivery to HIV-infected cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of infected cells. Whole blood studies show that the formulation is taken up by 90% of the lymphocytes after 8 hours at 37°C. 15 Preliminary biodistribution and pharmacokinetic studies yielded 70% of the injected dose/gm of tissue in the spleen after one hour following intravenous administration.

Intraperitoneal administration also leads to entry 20 into the circulation with the molecular weight or size of the ribozyme-delivery vehicle complex controlling the rate of entry.

Liposomes injected intravenously show accumulation in the liver, lung and spleen. The composition and size can 25 be adjusted so that this accumulation represents 30% to 40% of the injected dose. The rest is left to circulate in the blood stream for up to 24 hours.

The chosen method of delivery will result in cytoplasmic accumulation in the afflicted cells and 30 molecules should have some nuclease-resistance for optimal dosing. Nuclear delivery may be used but is less preferable. Most preferred delivery methods include liposomes (10-400 nm), hydrogels, controlled-release polymers, microinjection or electroporation (for ex vivo treatments) 35 and other pharmaceutically applicable vehicles. The dosage will depend upon the disease indication and the route of administration but should be between 100-200

mg/kg of body weight/day. The duration of treatment will extend through the course of the disease symptoms, usually at least 14-16 days and possibly continuously. Multiple daily doses are anticipated for topical applications, 5 ocular applications and vaginal applications. The number of doses will depend upon disease delivery vehicle and efficacy data from clinical trials.

Establishment of therapeutic levels of ribozyme within the cell is dependent upon the rate of uptake and degradation. 10 Decreasing the degree of degradation will prolong the intracellular half-life of the ribozyme. Thus, chemically modified ribozymes, e.g., with modification of the phosphate backbone, or capping of the 5' and 3' ends of the ribozyme with nucleotide analogs may require 15 different dosaging. Descriptions of useful systems are provided in the art cited above, all of which is hereby incorporated by reference herein.

Particular diseases that may be treated in this manner include any disease which can be treated by such RNAs, for 20 example, HSV, HBV, EBV, and HIV infection; as well as various carriers (where the target molecule is located in a known cellular compartment).

Any disease caused by a specific set of mutations in a given genes RNA is potentially treatable by using target 25 trans-splicing to correct such defective RNAs. Such diseases would include:

- A. β -globin diseases (such as sickle cell anemia), cystic fibrosis, as well as any other genetic diseases caused by a point mutations or deletions in RNA.
- 30 B. Cancers caused by specific mutant oncogene encoding RNAs (e.g. bcr-abl mRNAs, mutant p53 mRNAs).
- C. Genetic diseases caused by unstable trinucleotide repeats in RNAs (e.g. Huntington's disease, fragile X syndrome).

35 Other embodiments are within the following claims.

Claims

1. Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule, comprising the step of:

5 contacting said target nucleic acid molecule with a catalytic nucleic acid molecule comprising said separate nucleic acid molecule under conditions in which at least a portion of said separate nucleic acid molecule is spliced with at least a portion of said target nucleic
10 acid molecule to form a chimeric nucleic acid molecule; wherein said catalytic nucleic acid molecule is not naturally associated with said separate nucleic acid molecule.

2. Method for splicing a target nucleic acid molecule with a separate nucleic molecule, comprising the step of:

15 contacting said target nucleic acid molecule with said separate nucleic acid molecule in the presence of one or more spliceosomes or splicing factors under conditions in which at least a portion of said separate nucleic acid molecule is spliced with at least a portion of said target
20 nucleic acid molecule to form a chimeric nucleic acid molecule.

3. The method of claim 1, wherein said catalytic nucleic acid molecule is active to cleave said target nucleic acid molecule and to splice said separate nucleic acid molecule with said target nucleic acid molecule.

4. The method of claim 1, wherein said catalytic nucleic acid molecule is a group I or group II intron molecule.

5. The method of claim 1 or 2, wherein said
30 contacting is in vitro.

6. The method of claim 1 or 2, wherein said contacting is in vivo.

7. The method of claim 1 or 2, wherein said target nucleic acid is an RNA molecule.

8. The method of claim 1 or 2, wherein said separate nucleic acid molecule is an RNA molecule.

5 9. The method of claim 1 or 2, wherein said target nucleic acid molecule includes a nucleic acid sequence deleterious to the organism in which it is located and wherein said separate nucleic acid molecule is adapted to correct said defect after splicing with said target
10 nucleic acid molecule.

10. The method of claim 1 or 2, wherein said target nucleic acid molecule is a virus and said separate nucleic acid molecule encodes a dominant negative allele for said virus.

15 11. The method of claim 1 or 2, wherein said contacting comprises providing a vector encoding said catalytic nucleic acid molecule comprising said separate nucleic acid molecule.

12. A catalytic nucleic acid molecule, comprising: a
20 separate nucleic acid molecule adapted for splicing with a target nucleic acid molecule, wherein said separate nucleic acid molecule encodes at least a portion of a protein adapted to be expressed when spliced with said target nucleic acid molecule.

1/10

FIG. 1a.


A. SELF-SPlicing OF THE GROUP I INTRON FROM *TETRAHYMENA THERMOPHILA* pre-rRNA

FIG. 1b.

B. TRANS-SPlicing OF A 3' EXON ONTO A DINUCLEOTIDE 5' EXON






FIG. 1c.


C. TARGETED TRANS-SPlicing OF A NEW 3' EXON ONTO A TARGETED 5' EXON



2/10




3/10



4/10

FIG. 3.



5/10





FIG. 4.


6/10

FIG. 5.



7/10

FIG. 6a.
A. TRANS-SPlicing SCHEME




SUBSTITUTE SHEET (RULE 26)


8/10

FIG. 6b.

B. Trans-splicing reaction




9/10
FIG. 7.



SUBSTITUTE SHEET (RULE 26)

10/10
FIG. 8.



INTERNATIONAL SEARCH REPORT

Internat 1 Application No
PCT/US 94/12976A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/52 C12N9/00 A61K48/00 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbol(s))
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NUCLEIC ACIDS RESEARCH, vol. 21, no.2, 11 January 1993 ARLINGTON, VIRGINIA US, pages 185-190, KOMATSU, Y. ET AL. 'Cross-ligation and exchange reactions catalyzed by hairpin ribozymes' see the whole document ---	1,3,5-8, 11,12
Y	WO,A,92 13090 (GEN HOSPITAL CORP) 6 August 1992 see page 8, line 28 - page 9, line 20 see page 10, line 30 - page 11, line 3 see page 15, line 1 - line 17 see page 25, line 5 - page 26, line 28 see page 38, paragraphs V and VI ---	1-12
Y	WO,A,92 13090 (GEN HOSPITAL CORP) 6 August 1992 see page 8, line 28 - page 9, line 20 see page 10, line 30 - page 11, line 3 see page 15, line 1 - line 17 see page 25, line 5 - page 26, line 28 see page 38, paragraphs V and VI ---	1,3-9, 11,12
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *'&' document member of the same patent family

1

Date of the actual completion of the international search

10 March 1995

Date of mailing of the international search report

16.03.95

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/US 94/12976

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCIENCE, vol. 253, 12 July 1991 LANCASTER, PA US, pages 157-163, GUTHRIE, C. 'Messenger RNA splicing in yeast: clues to why the spliceosome is a ribonucleoprotein' cited in the application see the whole document ---	2
Y	NATURE, vol. 335, 29 September 1988 LONDON GB, pages 452-454, FRIEDMAN, A. ET AL. 'Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus' cited in the application see the whole document ---	10
A,0	JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 12D, 4 April 1988 - 16 April 1988 NEW YORK, USA, page 28 FLANEYAN, J. & CECH, T. 'Tetrahymena ribozyme catalyzes trans-splicing of model oligoribonucleotide substrates' see abstract ---	1
A	SCIENCE, vol. 236, 19 June 1987 LANCASTER, PA US, pages 1532-1539, CECH, T. 'The chemistry of self-splicing RNA and RNA enzymes' see page 1532, right column - page 1533, right column, line 5 see figure 6C ---	1
A	WO,A,88 04300 (UNIVERSITY PATENTS INC) 16 June 1988 see page 16, line 11 - page 20 see example VII ---	1
P,X	NATURE, vol. 371, 13 October 1994 LONDON GB, pages 619-622, SULLENGER, B. & CECH, T. 'Ribozyme-mediated repair of defective mRNA by targeted trans-splicing' see the whole document ---	1-12
1	-/-	

INTERNATIONAL SEARCH REPORTInternat'l Application No
PCT/US 94/12976

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CELL, vol. 43, December 1985 CAMBRIDGE, MA US, pages 431-437, INOUE, T. ET AL. 'Intermolecular exon ligation of the rRNA precursor of Tetrahymena: oligonucleotides can function as 5' exons' cited in the application -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/12976

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 1-4, 6, 9-11 (as far as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No
PCT/US 94/12976

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9213090	06-08-92	AU-B-	654330	03-11-94
		AU-A-	1234492	27-08-92
		CN-A-	1065682	28-10-92
		EP-A-	0567568	03-11-93
		JP-T-	6504444	26-05-94
-----	-----	-----	-----	-----
WO-A-8804300	16-06-88	US-A-	4987071	22-01-91
		EP-A-	0291533	23-11-88
		JP-T-	1501445	25-05-89
		US-A-	5037746	06-08-91
		US-A-	5116742	26-05-92
		US-A-	5093246	03-03-92
		US-A-	5354855	11-10-94
-----	-----	-----	-----	-----

CHOATE, HALL & STEWART
M E M O R A N D U M

To: Beacon Hill Research & Service Group, Inc. (451-5411)
DT: September 8, 1998
From: Linda D. Kostrubanic (617-248-4013)
RE: 2000765-0001/bhj

Please retrieve the following highlighted entries.
thanks.